RxDoctor Payments Data

Susan Sanford

Family · la Grange, KYNPI 1467803825

Payments from drug & device makers

$3,122in general payments, 2019–2025

Across 183 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$341
  • Lilly USA, LLC$199
  • Novo Nordisk$197
  • Electronic Waveform Lab, Inc.$183
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$178
  • plus $767 from 19 others

What the payments were for

  • Food & beverage$3,10699%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,122 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,098
Medicare patients
44
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$58,464
MounjaroTirzepatide54$52,330
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$38,107
FarxigaDapagliflozin Propanediol35$35,818
EliquisApixaban38$32,589
JanuviaSitagliptin Phosphate12$17,184
Tresiba Flextouch U-100Insulin Degludec27$15,308
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$12,539
JardianceEmpagliflozin11$9,888
LinzessLinaclotide12$6,378
Sumatriptan Succinate12$3,307
Insulin Lispro Kwikpen U-100Insulin Lispro15$3,001
Albuterol Sulfate HfaAlbuterol Sulfate73$2,347
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,065
Novolog FlexpenInsulin Aspart12$1,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$197$58,46455 claims
Lilly USA, LLCMounjaro$199$52,33054 claims
GSKTrelegy Ellipta$45$38,10737 claims
AstraZenecaFarxiga$341$35,81835 claims
MerckJanuvia$33$17,18412 claims
AbbVieLinzess$1,256$6,37812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in la Grange

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →